International biopharmaceutical business leader Robert A. Bradway has been elected to the USC Board of Trustees. Bradway is chairman and CEO of Amgen Inc., the world’s largest independent biotechnology company.
Headquartered in Thousand Oaks, Calif., Amgen has 20,000 employees in more than 50 countries, having served more than 25 million patients. The company specializes in discovering, developing, manufacturing and delivering innovative human therapeutics in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses.
“Bob Bradway stands among our nation’s leading executives in the field of biotechnology,” said USC President C. L. Max Nikias. “Under his visionary guidance, Amgen has significantly expanded its reach, while continuing to provide tremendously innovative therapies that restore health and save lives. Mr. Bradway brings to our board his exceptional experience and expertise, as well as his commitment to applying research to better our society.”
Bradway holds a bachelor’s degree in biology from Amherst College and a master’s degree in business administration from Harvard University.
A former investment banker, he joined Amgen in 2006 as vice president for operations strategy and was quickly promoted to executive vice president and chief financial officer. In 2010, he was named president and chief operating officer, and in 2011 he joined Amgen’s board of directors. He became the company’s chief executive officer in 2012, and its chairman in 2013.
Previously, Bradway had been managing director at Morgan Stanley in London, with responsibility for the firm’s banking department and corporate finance activities in Europe. His relationship with Morgan Stanley began in 1985, when Bradway joined the New York office as a health care industry investment banker. He later moved to London to head the firm’s international health care investment banking activities before assuming broader corporate finance management responsibilities.
In addition to being a USC trustee, Bradway serves on the advisory board of USC’s Leonard D. Schaeffer Center for Health Policy & Economics. He is a member of the board of directors of Norfolk Southern Corp., serving on its audit and governance committees.
—By Diane Krieger